Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow Polish Data Supplement
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cathcart, H. M.
Right arrow Articles by Poduslo, S. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cathcart, H. M.
Right arrow Articles by Poduslo, S. E.
Related Collections
Right arrow Alzheimer's disease
Right arrow All Genetics
Right arrow Association studies in genetics
NEUROLOGY 2005;64:755-757
© 2005 American Academy of Neurology
Brief Communications

Cystatin C as a risk factor for Alzheimer disease

H. M. Cathcart, MS, R. Huang, MD, I. S. Lanham, BS, E. H. Corder, PhD and S. E. Poduslo, PhD

From the Institute of Molecular Medicine and Genetics (Drs. Huang and Poduslo, H.M. Cathcart, and I.S. Lanham), Department of Neurology (Dr. Poduslo), Medical College of Georgia, Augusta, GA; Veteran Affairs Medical Center (Dr. Poduslo), Augusta, GA; and Center for Demographic Studies (Dr. Corder), Duke University, Durham, NC.

Address correspondence and reprint requests to Dr. S.E. Poduslo, IMMAG, Medical College of Georgia, 1120 15th Street, Augusta, GA 30912; e-mail: spoduslo{at}mail.mcg.edu

Cystatin C, a protease inhibitor with widespread distribution, is upregulated in response to injury. Levels are elevated in the brains of patients with Alzheimer disease (AD). We compared frequencies for the CST 3 exon 1 polymorphism in patients with AD and controls. A proportional odds model indicated that the CST 3 A and APOE4 combination carried a high risk: a 14-fold elevation for men and 16-fold for women. These risks apply to risk at ages older than 64 years and to a shift in onset to ages younger than 65 years.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by AAN Enterprises, Inc.